NASDAQ:HEPA Hepion Pharmaceuticals (HEPA) Stock Price, News & Analysis → Major Elon Musk Crypto Leak Revealed (From Crypto 101 Media) (Ad) Free HEPA Stock Alerts $2.49 -0.01 (-0.40%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$2.42▼$2.5350-Day Range$1.51▼$3.1752-Week Range$1.49▼$20.66Volume21,288 shsAverage Volume79,044 shsMarket Capitalization$10.81 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Hepion Pharmaceuticals alerts: Email Address Hepion Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.32% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.72Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($10.98) to ($11.43) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.60 out of 5 starsMedical Sector879th out of 938 stocksPharmaceutical Preparations Industry388th out of 417 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Hepion Pharmaceuticals. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.32% of the float of Hepion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverHepion Pharmaceuticals has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Hepion Pharmaceuticals has recently decreased by 19.60%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHepion Pharmaceuticals does not currently pay a dividend.Dividend GrowthHepion Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HEPA. Previous Next 2.6 News and Social Media Coverage News SentimentHepion Pharmaceuticals has a news sentiment score of 0.72. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Hepion Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for HEPA on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Hepion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Hepion Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.95% of the stock of Hepion Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 17.24% of the stock of Hepion Pharmaceuticals is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Hepion Pharmaceuticals are expected to decrease in the coming year, from ($10.98) to ($11.43) per share.Price to Book Value per Share RatioHepion Pharmaceuticals has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto 101 MediaMajor Elon Musk Crypto Leak RevealedReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto market. Musk revealed a "mind-blowing" plan to take over the global payment system. In his own words, the world's richest man said "you won't need a bank account." Prominent voices in crypto believe what comes next will mirror a crypto mass adoption similar to the one that triggered bitcoin's last bull run.Click here now to get your copy. About Hepion Pharmaceuticals Stock (NASDAQ:HEPA)Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Edison, New Jersey.Read More HEPA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HEPA Stock News HeadlinesMarch 27, 2024 | americanbankingnews.comHepion Pharmaceuticals (NASDAQ:HEPA) Trading 3.1% Higher March 24, 2024 | investing.comHepion Pharmaceuticals Inc (HEPA)March 29, 2024 | WealthPress (Ad)A lot of people are making this costly mistakeYou may have heard the saying “options are risky” … And, they can be. But only if you use them the way a lot of folks do. A lot of people think of BUYING speculative options when they talk about options. And BUYING low probability, speculative options is definitely risky… It’s how some folks leverage large sums of money hoping that a stock moves in the “right” direction over a certain period of time. March 6, 2024 | globenewswire.comHepion Pharmaceuticals Strengthens Board of Directors with Appointment of Michael PurcellFebruary 16, 2024 | finance.yahoo.comHepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsFebruary 16, 2024 | globenewswire.comHepion Pharmaceuticals Announces Exercise of Warrants for Approximately $2.0 Million Aggregate Gross ProceedsJanuary 3, 2024 | finance.yahoo.comHepion Pharmaceuticals to Present at NASH-TAG 2024December 7, 2023 | finanznachrichten.deHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesMarch 29, 2024 | Insiders Exposed (Ad)This consistently signaled gains of 453%... 610%... and even 1036%...It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.December 7, 2023 | realmoney.thestreet.comHepion Pharmaceuticals downgraded to Hold from Buy at BrooklineDecember 7, 2023 | marketwatch.comHepion Sets Restructuring; To Explore Strategic OptionsDecember 7, 2023 | finance.yahoo.comHepion Pharmaceuticals Announces Restructuring Plan to Enhance Shareholder Value and Management ChangesNovember 28, 2023 | finance.yahoo.comHepion Pharmaceuticals to Present at the 7th Obesity & NASH Drug Development SummitNovember 28, 2023 | msn.comHepion Pharmaceuticals says Wijngaard buys 5K shares in coNovember 13, 2023 | finance.yahoo.comHepion Pharmaceuticals Announces Major Reductions in Liver Stiffness with Rencofilstat Treatment in 17-week Phase 2 Study of Advanced (F3) MASH Liver DiseaseNovember 10, 2023 | benzinga.comHepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 'ALTITUDE-NASH' Liver Function Trial of RencofilstatNovember 10, 2023 | finance.yahoo.comHepion Pharmaceuticals Schedules Conference Call to Review Additional Efficacy Data from Phase 2 ‘ALTITUDE-NASH’ Liver Function Trial of RencofilstatOctober 31, 2023 | money.usnews.comGSK Signs $1 Billion Deal for Exclusive License to J&J's Hepatitis B TherapyOctober 25, 2023 | finanznachrichten.deHepion Pharmaceuticals, Inc.: Hepion Pharmaceuticals' Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer ModelOctober 25, 2023 | finance.yahoo.comHepion Pharmaceuticals’ Rencofilstat Demonstrates Anti-Cancer Activity in Hepatitis C-Associated Cancer ModelSeptember 29, 2023 | msn.comHepion to sell $5M in shares through registered direct offeringSeptember 29, 2023 | finance.yahoo.comHepion Pharmaceuticals Announces $5.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market under Nasdaq RulesSeptember 21, 2023 | finance.yahoo.comHepion Pharmaceuticals to Participate in 2023 Cantor Global Healthcare ConferenceSeptember 21, 2023 | finance.yahoo.comNew Anti-Cancer Opportunities Revealed for Hepion Pharmaceuticals’ Rencofilstat in Cancer Screening ProgramSeptember 19, 2023 | finance.yahoo.comHere's Why Hepion Pharmaceuticals (NASDAQ:HEPA) Must Use Its Cash WiselySeptember 19, 2023 | finance.yahoo.comHepion Pharmaceuticals Discovers Novel Rencofilstat Action in Liver CancerSeptember 18, 2023 | finance.yahoo.comInsider Buying: Robert Foster Acquires 1,600 Shares of Hepion Pharmaceuticals IncSee More Headlines Receive HEPA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hepion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2020Today3/28/2024Next Earnings (Estimated)4/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:HEPA CUSIPN/A CIK1583771 Webwww.hepionpharma.com Phone(732) 902-4000Fax732-902-4100Employees25Year Founded2013Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-42,200,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-145.58% Return on Assets-104.36% Debt Debt-to-Equity RatioN/A Current Ratio3.32 Quick Ratio3.32 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.64 per share Price / Book0.20Miscellaneous Outstanding Shares4,340,000Free Float4,253,000Market Cap$10.81 million OptionableNo Data Beta1.56 Social Links Investing Strategies To Help Grow Your Retirement IncomeNeed to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.Get This Free Report Key ExecutivesMr. John T. Cavan (Age 66)Interim CEO & CFO Comp: $495.33kSharen PyatetskayaDirector of Investor RelationsKey CompetitorsGalera TherapeuticsNASDAQ:GRTXASLAN PharmaceuticalsNASDAQ:ASLNCadrenal TherapeuticsNASDAQ:CVKDAeterna ZentarisNASDAQ:AEZSMustang BioNASDAQ:MBIOView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 5,167 shares on 3/11/2024Ownership: 3.695%Virtu Financial LLCBought 12,489 shares on 2/26/2024Ownership: 0.288%Vanguard Group Inc.Sold 5,167 shares on 2/15/2024Ownership: 3.696%Armistice Capital LLCBought 20,393 shares on 2/13/2024Ownership: 9.631%Peter WijngaardBought 2,500 shares on 11/27/2023Total: $7,625.00 ($3.05/share)View All Insider TransactionsView All Institutional Transactions HEPA Stock Analysis - Frequently Asked Questions Should I buy or sell Hepion Pharmaceuticals stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hepion Pharmaceuticals in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HEPA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HEPA, but not buy additional shares or sell existing shares. View HEPA analyst ratings or view top-rated stocks. How have HEPA shares performed in 2024? Hepion Pharmaceuticals' stock was trading at $3.24 at the start of the year. Since then, HEPA stock has decreased by 23.1% and is now trading at $2.49. View the best growth stocks for 2024 here. Are investors shorting Hepion Pharmaceuticals? Hepion Pharmaceuticals saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 56,600 shares, a decline of 19.6% from the February 29th total of 70,400 shares. Based on an average daily trading volume, of 78,700 shares, the days-to-cover ratio is currently 0.7 days. Currently, 1.3% of the company's shares are sold short. View Hepion Pharmaceuticals' Short Interest. When is Hepion Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our HEPA earnings forecast. How were Hepion Pharmaceuticals' earnings last quarter? Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) posted its earnings results on Sunday, November, 15th. The company reported ($13.80) EPS for the quarter, missing analysts' consensus estimates of ($10.20) by $3.60. When did Hepion Pharmaceuticals' stock split? Hepion Pharmaceuticals's stock reverse split on Thursday, May 11th 2023. The 1-20 reverse split was announced on Thursday, May 11th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 11th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What other stocks do shareholders of Hepion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Hepion Pharmaceuticals investors own include Bausch Health Companies (BHC), Axsome Therapeutics (AXSM), Archrock (AROC), Alector (ALEC), AIM ImmunoTech (AIM), Applied Genetic Technologies (AGTC), Abbott Laboratories (ABT) and Ambev (ABEV). Who are Hepion Pharmaceuticals' major shareholders? Hepion Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Armistice Capital LLC (9.63%), Vanguard Group Inc. (3.70%), Vanguard Group Inc. (3.69%), Virtu Financial LLC (0.29%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Peter Wijngaard and Robert T Foster. View institutional ownership trends. How do I buy shares of Hepion Pharmaceuticals? Shares of HEPA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HEPA) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI healthcare stock poised for 36,996% growth?Behind the Markets Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hepion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.